Health Care • Medical/Dental Instruments
$6.56 ▲ +0.10
(+1.55%)
MKT CAP: $371.7M • VOL: 1.11M
52W L $3 52W H $15
ROARABLE / RQD
B • 74/100
PIOTROSKI
7 / 9
EMBC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.08B | $1.12B | $1.12B |
| YoY Revenue Growth % | -3.8% | +0.2% | — |
| Gross Profit | $676.8M | $735.2M | — |
| Gross Margin % | 62.6% | 65.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $242.1M | $166.8M | $221.5M |
| Operating Margin % | 22.4% | 14.9% | 19.8% |
| Net Income (GAAP) | $95.4M | $78.3M | $70.4M |
| EBITDA (Normalized) | $249.5M | $179.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $191.7M | $35.7M | $67.7M |
| Capital Expenditures (CapEx) | $9.3M | $15.8M | — |
| Free Cash Flow (FCF) | $182.4M | $19.9M | $67.7M |
| FCF Margin % | 16.9% | 1.8% | 6.0% |
| Return on Invested Capital (ROIC %) | 35.5% | 23.7% | — |
| Cash & Short-Term Equivalents | $201.3M | $210.0M | — |
| Total Debt (Short + Long Term) | $1.35B | $1.53B | — |
| Total Stockholders' Equity | -$613.1M | -$768.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EMBC.